Talk Around Town: BioOrbit Claims Its £9.8M Seed Round Could Crystallise Cancer Drugs in Orbit

What Folks Are Hollerin' About

Well, butter my biscuit and call it a Tuesday — London startup BioOrbit has come roaring out of the barn claiming it raised £9.8 million (about $13.2M) in a seed round, according to the company's own announcement. Trade outlets including Startups Magazine, the BioIndustry Association, and European Biotechnology Magazine all picked up the story, though most of them were drawing from the same press-release watering hole. The round, BioOrbit says, was co-led by LocalGlobe and Breega, with Auxxo, Seedcamp, Type One, 7percent, and a mess of angels throwing in as well.

The company, founded in 2023 by Dr Katie King and Dr Leonor Teles, describes itself as building hardware to crystallise protein-based biologic drugs aboard orbital platforms in low-Earth orbit. The pitch, as BioOrbit tells it, is that the weightless environment of space lets protein molecules line up into tighter, more uniform crystals than anything you could wrangle out of an Earth-based lab — sort of like how you get a prettier snowflake up on a cold mountaintop than you do in a swampy parking lot in August.

The Grandest Claim at the County Fair

BioOrbit claims this £9.8M haul is the single largest seed round ever raised for in-space manufacturing anywhere on God's green Earth — or, more accurately, above it. That is a heck of a ribbon to pin on your prize pig, but Tech Funding News, which covered the round, explicitly noted that the superlative has not been independently verified. It is worth pointing out that US competitor Varda Space has raised a total of $329M and has already completed actual orbital drug-crystal return missions, which makes the size comparison feel a little like bragging you caught the biggest catfish when your neighbor's got a marlin on the dock.

Government voices have lent the announcement some shine. UK Space Minister Liz Lloyd and Lord David Willetts, chair of the UK Space Agency, both offered attributed endorsements of BioOrbit as an exciting British startup positioned well for cancer immunotherapy innovation. Those are politicians saying nice things at a ribbon-cutting, not scientists signing off on a lab report, so hold onto your hat accordingly.

What Is Actually Known, No Bull

The funding round itself is confirmed: £9.8M, co-led by LocalGlobe and Breega, with the named co-investors participating. That part is not in dispute. What BioOrbit has actually built is described by the company as BOX — a compact, modular, autonomous manufacturing unit roughly the size of a microwave — designed to crystallise protein-based drugs in low-Earth orbit and, the company says, scale that process from a one-off experiment into something repeatable at an industrial level.

The UK Space Agency has confirmed awarding BioOrbit a £250,000 contract under what the agency calls the 'PHARM' study, intended to design an end-to-end, regulatory-compliant mission architecture for in-orbit drug manufacturing. BioOrbit also says it is collaborating with the MHRA and the Regulatory Innovation Office on what it describes as a first-of-its-kind pharmaceutical regulatory pathway for medicines made off-planet. According to Clinical Trials Arena's independent reporting from mid-2025, BioOrbit CEO Dr Katie King stated that a proof-of-concept manufacturing line was planned to fly to the ISS that summer, with meaningful crystal production targeted for 2026 and pre-clinical trials aimed at 2026 or 2027.

What Nobody Can Confirm Yet

Here is where the barn door swings wide open and the horses ain't all accounted for. BioOrbit's central scientific premise — that microgravity produces pharmaceutically superior protein crystals at a scale and consistency useful for actual drug manufacturing — is based entirely on company-reported data and earlier general ISS experiments. No independent, peer-reviewed validation of BioOrbit's own crystallisation results has been published anywhere that this publication could locate. That is not proof the concept is wrong; it is proof nobody outside the company has kicked the tires yet.

The company's stated ambition to convert intravenous cancer and chronic-disease biologics into subcutaneous, self-injectable treatments patients can use at home is a compelling vision, according to BioOrbit's own marketing materials. But that outcome sits on top of a towering stack of unresolved questions: whether the crystals will actually work better at scale, whether launch costs will ever be commercially viable, whether quality control can be maintained across both orbital and terrestrial manufacturing sites, and whether the MHRA will eventually sign off on drugs made in a place that doesn't even have a zip code.

A Wired article was flagged as a trend signal for this topic via BioOrbit's own LinkedIn feed, but its full text was not retrievable for independent review. Claims attributed to that piece about a 'longevity lab launch into orbit' could not be confirmed as describing anything distinct from BioOrbit's general drug-manufacturing pitch, so we are treating it as a single self-reported signal and nothing more.

The Science Behind the Sizzle

The broader scientific neighborhood BioOrbit is building in does have some independent credibility, even if BioOrbit's own corner of it is unverified. Research published in Cell Stem Cell and covered by Longevity.Technology found that human stem cells exposed to actual spaceflight rapidly accumulated features normally associated with decades of biological wear and tear — essentially aging fast in orbit. That finding supports the general concept that microgravity is a powerful biological stressor that can accelerate certain processes, which is at least adjacent to what BioOrbit is claiming about crystal formation. It does not, however, confirm BioOrbit's specific manufacturing thesis.

Think of it this way: knowing that a pressure cooker makes food cook faster does not automatically mean your aunt's new space-age cooker is going to turn out a better pot roast than she claims. The physics can be real while the specific product outcome stays unproven.

Our Analysis: Promising Moonshine or the Real Thing?

Analysis, not reporting: BioOrbit has done a genuinely impressive job of assembling credible institutional backers, a government contract, and regulatory dialogue around what is still a very early-stage, scientifically unverified bet. The fact that the UK Space Agency handed over £250,000 for a regulatory-pathway study suggests officialdom thinks the concept is at least worth mapping out, which is a meaningful signal even if it is not a technical endorsement. The VC roster — LocalGlobe and Breega are not fly-by-night operations — indicates sophisticated investors ran some due diligence before saddling up.

That said, this publication's analysis is that BioOrbit sits squarely in the category of 'bold pitch backed by plausible science but not yet backed by independent results.' The timeline Dr King described to Clinical Trials Arena — ISS proof-of-concept this summer, meaningful crystals in 2026, pre-clinical trials by 2027, commercial scale sometime after that — is ambitious in a field where even the regulatory vocabulary does not fully exist yet. The practical hurdles flagged by specialist and trade press, including launch costs, cross-site quality control, and regulatory approvals for off-planet medicine, are not trivial speed bumps. They are the kind of deep ruts that have swallowed many a promising startup truck. Keep an eye on BioOrbit, but do not go canceling your hospital IV appointments just yet.